Literature DB >> 2405807

Sensorimotor gating and schizophrenia. Human and animal model studies.

D L Braff1, M A Geyer.   

Abstract

Human and animal model studies of sensorimotor gating allow us to understand the functional significance of attentional abnormalities and monoaminergic alterations in patients with schizophrenic disorders. Clinically, schizophrenic patients report oversensitivity to sensory stimulation that theoretically correlates with stimulus overload and leads to cognitive fragmentation. Paradigms using cortical event-related potentials and the prepulse inhibition of startle responses show that schizophrenic patients also have impaired central nervous system inhibition (sensorimotor gating). Animal model studies demonstrate that increased systemic aminergic activity and increased nucleus accumbens dopamine tone causes sensorimotor gating failure, similar to that seen in schizophrenic patients. The time course of the observed schizophrenic and animal model deficits is compatible with the "temporal map" of monoaminergic neuron functions (le, several hundred milliseconds). Studies of sensorimotor gating allow investigators to comment on the spatial and temporal mapping of neurons, trait and state deficits, and vulnerability factors in the schizophrenic spectrum of disorders. By translating attentional theories into testable hypotheses, the neurobiology of schizophrenic disorders becomes clearer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405807     DOI: 10.1001/archpsyc.1990.01810140081011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  318 in total

Review 1.  The alpha7 nicotinic acetylcholine receptor in neuronal plasticity.

Authors:  R S Broide; F M Leslie
Journal:  Mol Neurobiol       Date:  1999-08       Impact factor: 5.590

2.  Reflex excitability regulates prepulse inhibition.

Authors:  E J Schicatano; K R Peshori; R Gopalaswamy; E Sahay; C Evinger
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 3.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

4.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

5.  Developmental markers of psychiatric disorders as identified by sensorimotor gating.

Authors:  Susan B. Powell; Mark A. Geyer
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

6.  Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia.

Authors:  Tsuyoshi Miyakawa; Lorene M Leiter; David J Gerber; Raul R Gainetdinov; Tatyana D Sotnikova; Hongkui Zeng; Marc G Caron; Susumu Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-08       Impact factor: 11.205

7.  Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats.

Authors:  K Wedzony; K Gołembiowska; M Zazula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

8.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

9.  Disruption of prepulse inhibition of the startle reflex by the preferential D(3) agonist ropinirole in healthy males.

Authors:  Stella G Giakoumaki; Panos Roussos; Sophia Frangou; Panos Bitsios
Journal:  Psychopharmacology (Berl)       Date:  2007-06-20       Impact factor: 4.530

10.  Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

Authors:  N R Swerdlow; J Paulsen; D L Braff; N Butters; M A Geyer; M R Swenson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.